The estimated Net Worth of Ian Clements is at least $1.35 Million dollars as of 24 November 2021. Dr Clements owns over 1,450 units of Mirum Pharmaceuticals Inc stock worth over $777,892 and over the last 5 years he sold MIRM stock worth over $30,315. In addition, he makes $541,146 as Chief Financial Officer at Mirum Pharmaceuticals Inc.
Dr has made over 4 trades of the Mirum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,450 units of MIRM stock worth $20,503 on 24 November 2021.
The largest trade he's ever made was buying 4,000 units of Mirum Pharmaceuticals Inc stock on 6 September 2019 worth over $46,040. On average, Dr trades about 791 units every 68 days since 2019. As of 24 November 2021 he still owns at least 18,561 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Dr Clements stock trades at the bottom of the page.
Dr. Ian Clements is the Chief Financial Officer at Mirum Pharmaceuticals Inc.
As the Chief Financial Officer of Mirum Pharmaceuticals Inc, the total compensation of Dr Clements at Mirum Pharmaceuticals Inc is $541,146. There are 5 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.
Dr Clements is 52, he's been the Chief Financial Officer of Mirum Pharmaceuticals Inc since . There are 5 older and 14 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
Ian's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: